Republican lawmakers are raising concerns that companies may face environmental barriers to manufacturing more pharmaceuticals and active pharmaceutical ingredients in the US, as the idea of onshoring gains popularity as an option for relieving generic drug shortages.
The 6 February House Ways and Means Committee hearing on drug shortages spent ample time discussing how the US could use legislative levers, such as the tax code, to encourage onshoring and reduce its dependence on foreign manufacturers, particularly